Pfizer pencils in $15B in 2030 revenue from future deals

Although Pfizer expects sales of its COVID-19 products to slow down in 2023, the pharma believes it has “more than enough capital to invest” in future deals meant to add roughly $15 billion to its top line in 2030.

In the company’s quarterly presentation Tuesday, Pfizer Inc. (NYSE:PFE) CEO Albert Bourla said products sourced via deals could supply a total of $25 billion in 2030 revenues. Therapies from four deals Pfizer has already made are likely to deliver about $10 billion, while future deals would account for the balance...